Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume
暂无分享,去创建一个
M. Mühlau | B. Hemmer | B. Wiestler | J. Kirschke | A. Berthele | V. Pongratz | M. Bussas | M. Lauerer | C. Zimmer
[1] Till F. M. Andlauer,et al. Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers , 2021, Multiple sclerosis.
[2] C. Pozzilli,et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study , 2021, JAMA neurology.
[3] M. Battaglini,et al. Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization , 2021, Annals of clinical and translational neurology.
[4] Maya B. Mathur,et al. A Simple, Interpretable Conversion from Pearson's Correlation to Cohen's d for Continuous Exposures. , 2020, Epidemiology.
[5] Christian Gaser,et al. Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion? , 2019, Brain and behavior.
[6] C. Granziera,et al. Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis , 2019, European Neurology.
[7] R. Chu,et al. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines , 2018, PloS one.
[8] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[9] M. Battaglini,et al. Deep grey matter volume loss drives disability worsening in multiple sclerosis , 2017, bioRxiv.
[10] C. Enzinger,et al. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice , 2016, Multiple sclerosis.
[11] Ludwig Kappos,et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.
[12] À. Rovira,et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.
[13] M. Battaglini,et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.
[14] F Fazekas,et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[15] R. Henry,et al. Regional grey matter atrophy in clinically isolated syndromes at presentation , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[16] Alan J. Thompson,et al. Localization of grey matter atrophy in early RRMS , 2006, Journal of Neurology.
[17] Mara Cercignani,et al. Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. , 2006, Archives of neurology.
[18] Marco Rovaris,et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[19] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[20] Marco Rovaris,et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.